Celularity Inc. Capital Expenditures Incurred but Not yet Paid
Celularity Inc. (CELU) reported Capital Expenditures Incurred but Not yet Paid of $87.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-04-30
- Celularity Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was $31.00K.
- Celularity Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $35.00K.
- Celularity Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was $10.00K, a 96.81% decline year-over-year.
- Celularity Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $11.00K, a 98.42% decline year-over-year.
- Celularity Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $87.00K, a 60.99% decline from fiscal 2023.
- Celularity Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $223.00K, a 67.35% decline from fiscal 2022.
- Celularity Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $683.00K, a 29.59% decline from fiscal 2021.
- Celularity Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $970.00K, a 20.35% increase from fiscal 2020.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $66.00K derived: sum of 2 quarters · filed 2026-04-30 | $76.00K derived: sum of 3 quarters · filed 2026-04-30 | $87.00K 10-K · filed 2026-04-30 |
| 2024-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $45.00K derived: sum of 2 quarters · filed 2025-11-14 | $56.00K 10-Q · filed 2025-11-14 | -$473.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $21.00K 10-Q · filed 2025-08-29 | -$508.00K derived: sum of 3 quarters · filed 2025-08-29 | -$766.00K derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $11.00K 10-Q · filed 2025-08-29 | -$518.00K derived: sum of 2 quarters · filed 2025-08-29 | -$776.00K derived: sum of 3 quarters · filed 2025-08-29 | -$463.00K derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | -$529.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$787.00K derived: sum of 2 quarters · filed 2025-05-08 | -$474.00K derived: sum of 3 quarters · filed 2025-05-08 | $223.00K 10-K · filed 2025-05-08 |
| 2023-09-30 | -$258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $55.00K derived: sum of 2 quarters · filed 2024-12-06 | $752.00K 10-Q · filed 2024-12-06 | $421.00K derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $313.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $1.01M 10-Q · filed 2024-11-07 | $679.00K derived: sum of 3 quarters · filed 2024-11-07 | $740.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $697.00K 10-Q · filed 2024-10-16 | $366.00K derived: sum of 2 quarters · filed 2024-10-16 | $427.00K derived: sum of 3 quarters · filed 2024-10-16 | $365.00K derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | -$331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -$270.00K derived: sum of 2 quarters · filed 2024-07-30 | -$332.00K derived: sum of 3 quarters · filed 2024-07-30 | $683.00K 10-K · filed 2024-07-30 |
| 2022-09-30 | $61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | -$1.00K derived: sum of 2 quarters · filed 2024-01-03 | $1.01M 10-Q · filed 2024-01-03 | $383.00K derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | -$62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $953.00K 10-Q · filed 2023-08-14 | $322.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.67M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.01M 10-Q · filed 2023-05-22 | $384.00K derived: sum of 2 quarters · filed 2023-05-22 | $1.73M derived: sum of 3 quarters · filed 2023-05-22 | $1.70M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | -$631.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $718.00K derived: sum of 2 quarters · filed 2023-03-31 | $683.00K derived: sum of 3 quarters · filed 2023-03-31 | $970.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.31M derived: sum of 2 quarters · filed 2022-11-10 | $1.60M 10-Q · filed 2022-11-10 | -$2.75M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $252.00K 10-Q · filed 2022-08-09 | -$4.09M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $287.00K 10-Q · filed 2022-05-16 | -$4.06M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $806.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $5.15M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |